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38 The Journal of Thoracic and Cardiobjectives: The American College of Surgeons Oncology Group trial Z0060 is a
rospective multi-institutional trial with a primary objective to evaluate whether
ositron emission tomography (PET) with F-18 fluorodeoxyglucose (FDG) detects
vidence of metastastic disease that precludes esophagectomy in patients with
sophageal cancer who are surgical candidates after routine staging.
ethods: Patients with resectable, biopsy-proven carcinoma were enrolled after
omputed tomography of chest and abdomen demonstrated no evidence of metas-
asis. FDG-PET was performed according to specified standards. FDG-PET findings
uggesting metastases required confirmation and patients without metastases on
ET were expected to proceed to surgery.
esults: A total of 262 patients were registered. Of these, 199 were deemed eligible
nd of these, 189 patients were evaluable. Seventy-three patients were ineligible or
nevaluable. Reasons for ineligibility included nonresectable disease by routine
taging (39), missing or outdated staging procedures (12), PET technical protocol
iolations (10), no cancer (4), pre-PET induction therapy (3), claustrophobia (1),
nd other causes (4). There were 145 (78%) patients who went on to have surgery,
2 (22%) who did not, and 2 patients for whom the surgical status was not
etermined. The reasons for no resection included the following: M1 disease found
y PET and confirmed (9), M1 disease found by PET and not confirmed (2), M1
isease at exploration not found by PET (7), decline or death before surgery (10),
atient refusal of surgery (7), unresectable local tumor at exploration (5), and
xtensive N1 disease precluding operation (2). Eight (4.2%) patients undergoing
esection had a recurrence in the first 6 months.
onclusions: Although 22% of eligible patients did not undergo esophagectomy,
DG-PET after standard clinical staging for esophageal carcinoma identified con-
rmed M1b disease in at least 4.8% (95% confidence interval: 2.2%-8.9%) of
atients before resection. Unconfirmed PET evidence of M1 disease and regional
denopathy (N1 disease) led to definitive nonsurgical or induction therapy in
dditional patients.
ccurate staging of esophageal cancer is essential to the ability to offer
patients treatment and an estimate of prognosis; it also allows adequate
interpretation and comparison of research studies. A significant advance in
he staging of esophageal cancer has been the use of 18F-fluorodeoxyglucose
ositron emission tomography (FDG-PET). This imaging modality takes advantage
f the fact that cancer cells have an increased cellular uptake of glucose and higher
ate of glycolysis than do normal cells. The radiolabeled glucose analog [18F]fluoro-
vascular Surgery ● March 2007
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TS-deoxy-D-glucose undergoes the same cellular uptake as
lucose, but, after phosphorylation, it is not further metab-
lized and is thus trapped in cells. PET, therefore, provides
nformation on the functional activity of a malignant lesion
ather than the strictly anatomic information that computed
omography (CT) provides.
Preliminary experience with FDG-PET in 36 patients
ith esophageal cancer was reported in 1997.1 Metastatic
isease was suspected in 7 (24%) of 29 patients who un-
erwent esophagectomy with curative intent, and therefore
hey underwent limited (confirmatory) tissue sampling
ather than resection. In 5 of these 7 patients, PET was able
o detect the metastatic focus whereas CT failed to reveal it.
n a later update, 58 patients with esophageal cancer were
valuated by FDG-PET. In 52 patients who were deemed
linically operable, 17 were found by PET to have distant
etastatic disease that precluded resection, whereas CT
etected metastases in only 5 of the 17 patients.2 A similar
tudy reported on 50 patients with esophageal cancer who
ere evaluated by FDG-PET.3 Thirty-five patients were
onsidered to have resectable disease by clinical evaluation.
owever, PET revealed increased FDG uptake beyond the
rimary tumor in 18 patients. Sixteen of these 18 patients
ere found to have true positive findings, which included
oth locoregional and distant metastatic disease. In partic-
lar, PET identified distant metastatic spread in 9 of the 18
atients, whereas CT failed to detect distant spread in any of
hese 9 patients. The use of PET for the detection of distant
etastases has been insufficiently studied, although reports
ave documented unexpected metastases in about 10% of
atients who are otherwise deemed candidates for surgery.4
ne consistent observation with PET staging of esophageal
ancer is that PET appears to be more sensitive than CT in
dentifying distant metastatic spread. In most of the above
eports, the majority of positive PET findings were vali-
ated by confirmatory tissue biopsies. This is clearly bene-
cial in that it spares these patients from undergoing an
nnecessary and noncurative esophagectomy. Unfortunately,
he preliminary data either involve small numbers of pa-
Abbreviations and Acronyms
ACOSOG American College of Surgeons Oncology
Group
CI  confidence interval
CT  computed tomography
FDG  18F-fluorodeoxyglucose
FDG-PET 18F-fluorodeoxyglucose positron emission
tomography
MRI magnetic resonance imaging
PET  positron emission tomographyients or else reflect studies that are methodologically sub- t
The Journal of Thoracicptimal. In addition, there are no definitive data concerning
alse positive PET findings.
To clarify the role of FDG-PET in the staging potentially
esectable esophageal cancer, the American College of Sur-
eons Oncology Group (ACOSOG) undertook the prospec-
ive multi-institutional trial Z0060. The primary objective
as to ascertain whether FDG-PET could detect metastatic
esions that would preclude esophageal resection in patients
elieved to be surgical candidates after standard imaging
rocedures.
aterials and Methods
egulatory Requirements
nvestigators registering patients to Z0060 were required to be
embers in good standing of ACOSOG, and the clinical site had
o be affiliated with an active ACOSOG institution. The Z0060
rotocol underwent institutional review board approval at all clin-
cal sites. Before enrolling patients in the study, the nuclear med-
cine investigator at participating institutions was required to sub-
it the detailed institutional protocol for PET imaging for Z0060
long with images and reports from three consecutive PET studies
or evaluation and approval by the ACOSOG PET Quality Assur-
nce Committee. The protocol was initially activated on November
2, 1999. The first patient was enrolled on February 15, 2000, and
he last patient was enrolled on July 10, 2004.
nclusion Criteria
atients older than 18 years of age with histologically confirmed
denocarcinoma or squamous cell carcinoma of the esophagus or
he gastroesophageal junction were considered eligible. The tu-
ors had to be at least 20 cm from the incisors and the patients had
o be free of metastatic disease after clinical and radiologic screen-
ng. Acceptable stages included T1-3 N0-1 M0-1a, and patients
ad to be medically fit for surgical staging and esophagectomy.
atients with poorly controlled diabetes mellitus were excluded, as
ere those unable to tolerate PET and those with a previous PET.
atients in whom neoadjuvant chemotherapy or chemoradiother-
py was planned were excluded initially, but concerns about en-
ollment led to a 2001 protocol amendment that allowed the
nclusion of such patients if PET was performed before neoadju-
ant therapy. Thirty-seven (19.6%) patients were enrolled before
he amendment and 152 (80.4%) were enrolled after the amend-
ent. Survivors of previous cancers were eligible only if they
ad undergone curative therapy and had been free of recurrence
or at least 5 years. It became apparent after enrollment of many
atients that the declaration of “free of metastatic disease” was
ubjective and many subjects enrolled had findings on CT scan
hat would be considered evidence of metastases. Noncalcified
ung lesions 4 mm or less were acceptable, whereas larger
esions were considered suggestive of metastases. Liver abnor-
alities described as cysts or likely cysts were accepted,
hereas lesions described as suggestive of metastases were not.
ther lesions that were described by the initial radiologist as
uggestive of metastasis were similarly excluded for analysis of
he primary end point.
and Cardiovascular Surgery ● Volume 133, Number 3 739
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TSadiologic Assessments
andatory radiologic staging assessments included chest and ab-
ominal CT. Bone scintigraphy and CT or magnetic resonance
maging (MRI) of the brain were required only if dictated by
linical signs, symptoms, or abnormal laboratory results. Radio-
ogic assessments were required to occur within 30 days before
tudy enrollment. CT from the thoracic inlet to the inferior tip of
he liver with intravenous contrast administration (unless contra-
ndicated) was performed with fourth-generation scanners capable
f high resolution, wide-dynamic range, and rapid screening. Col-
imation did not exceed 5 mm and the spacing between slice
enters was no greater than 8 mm.
linical Assessment
linical assessment was performed 30 days before registration and
ncluded an extended history and physical examination.
tudy Schema
atients whose disease was clinically staged as T1-3 N0-1 M0-1a
fter standard staging procedures and who were surgical candi-
ates were then registered to Z0060. Figure 1 illustrates the study
chema.
DG-PET
ull-ring dedicated scanners with bismuth germanate or sodium
odide detectors and with manufacturer-quoted in-plane spatial
esolution of less than 6 mm were used. Imaging with hybrid
ET/CT scanners, which became commercially available in 2002,
as not allowed in this study. The scanners underwent qualityontrol evaluation on each day imaging was performed. Patients c
40 The Journal of Thoracic and Cardiovascular Surgery ● Marcasted for at least 4 hours before the PET study, but were well
ydrated. The blood glucose concentration was determined imme-
iately before FDG administration, and the study was not per-
ormed if the blood glucose concentration was greater than 200
g/dL. FDG was obtained from a commercial supplier or was
repared and quality controlled by the routine method in use at the
erformance site in a manner consistent with applicable state and
ederal regulations. The radiochemical purity of the FDG was
equired to be greater than 90%. For facilities with a dedicated
ismuth germanate PET system, the FDG dose was 0.14 to 0.21
Ci/kg, with a minimum dose of 10 mCi. For facilities with a
odium iodide PET system, a dose of 0.07 mCi/kg was used.
PET imaging of the body began 45 to 60 minutes after FDG
njection. The patient was positioned supine, with the arms com-
ortably positioned above the head, whenever possible. The region
maged extended from the upper/mid neck to the upper thigh. A
eries of 5 or 6 overlapping transmission scans were obtained with
rotating 68Ge/68Ga rod source for each emission scan. A seg-
entation algorithm was used for all transmission scans, with scan
uration of 2 to 3 minutes. With dedicated sodium iodide PET
ystems, attenuation correction was done with a Cs-137 source in
ccordance with the manufacturer’s recommendations. Then, 5 or
corresponding emission images were performed. The PET im-
ges were reconstructed both with and without attenuation correc-
ion by standard vendor-provided reconstruction algorithms, using
ither filtered back projection with a Hann filter (frequency cutoff
.6  Nyquist  0.3 cycles/pixel) or an iterative reconstruction
ethod with an appropriate filter. Segmentation of transmission
mages was used for attenuation correction. Emission data were
Figure 1. The Z0060 study
schema.orrected for random coincidences and dead-time. The conven-
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G
TSional and PET imaging studies from the first 3 patients at each site
nd a 20% random sample of subsequent patients were reviewed
y 3 radiology/nuclear medicine investigators to document that
hese studies were performed per protocol specifications.
The PET images were interpreted by an experienced nuclear
hysician from each participating site. The transmission data were
eviewed with the emission scans to facilitate anatomic localiza-
ion of abnormal activity. The scans were reviewed in axial,
oronal, and sagittal planes and as maximum-pixel-intensity re-
rojection images. The images were initially interpreted without
nowledge of the results of previously obtained CT or other
maging studies or of surgical staging procedures. The images
ere then reinterpreted in combination with the CT and other
vailable imaging studies. These “unblinded” readings, which
ost closely reproduce routine clinical practice, were used for the
rimary end point analysis. Visual analysis involved the identifi-
ation of abnormal uptake as being greater than normal activity on
he attenuation-corrected images. The interpreter’s degree of sus-
icion that tumor was present at the primary tumor site, in locore-
ional nodes, and at distant metastatic sites was recorded on a
tandard case report form.
Abnormalities by PET that suggested metastases were required
o be confirmed by additional studies or biopsies. A PET-positive
epatic lesion required biopsy or fine-needle aspiration cytology to
onfirm metastatic disease. Benign cysts or hemangiomas could be
onfirmed by MRI or ultrasonography. PET-positive adrenal le-
ions required biopsy. Osseous abnormalities seen on PET had to
e evaluated by appropriate imaging studies (radiographs, CT,
RI, or repeat bone scintigraphy), by biopsy, or both. In the case
f multiple PET-positive lesions, a single positive biopsy specimen
f the most technically accessible site was considered satisfactory
onfirmation of positivity. In many instances, the PET-positive
esions were best accessed by laparotomy or thoracotomy, and
he effort to confirm the truth of a PET-detected metastasis took
lace at the time of the operation, but before actual resection of the
sophagus.
When PET did not identify distant metastasis, or when the
onfirmatory tests suggested or proved a false positive PET result,
he protocol intended that the patient would undergo surgical
esection with or without induction chemoradiotherapy. Resec-
ions without induction therapy were to take place within 30 days
f PET. No specific type of resection was required or suggested,
nd the details of surgical and perioperative care were left to the
reating surgeon. Perioperative events were captured and follow-up
t 6 months was required to document whether the patient was
live and whether there was evidence of recurrence.
tatistical Methods
he study was designed to assess the utility of FDG-PET using
ata from a clinical construct where the standard staging proce-
ures had to be performed and interpreted before the use of PET.
he hypothesis associated with the primary objective was as
ollows: H0: P  P0 against HA: P  PA, where H0 is the null
ypothesis, HA is the alternative hypothesis, P is a measure of the
tility of PET (surgery contraindicated by PET after negative
ndings using standard staging), P0 is the value of P regarded as
linically inconsequential, and P is the value of P regarded asA
linically consequential. The values for P0 and PA were set to be a
The Journal of Thoracic.05 and 0.1, respectively. A 2-stage accrual design was used to
llow for early termination if there was strong early evidence to
upport the null hypothesis.5 If the first stage of accrual consisting
f 120 patients did not support early suspension, a second stage of
ccrual of 115 patients for a total of 235 patients was targeted as
he final accrual goal. The decision rule for the first stage was to
erminate the study if 5 cases or fewer were observed that contra-
ndicated surgery. If 6 or more were observed, the study was to go
n to stage 2. If there were fewer than 18 cases among the first 235
ccrued cases where FDG-PET findings contraindicated surgery,
hen the study will have provided evidence in favor of the null
ypothesis. If 18 or more cases of 235 demonstrated FDG-PET
ndings contraindicating surgery, then the study will have pro-
ided evidence in favor of the alternative hypothesis. Point esti-
ates and 95% exact confidence intervals (CI) were calculated as
ppropriate. Resection rates were compared between those patients
eceiving and not receiving induction therapy using a 2 test.
esults
rom February 2000 to July 2004, 262 patients were regis-
ered to Z0060 from 23 institutions (Table E-1). Of the
egistered patients, 199 were deemed eligible and, of these,
89 patients were evaluable. Sixty-three patients were de-
lared ineligible and 10 were considered eligible but not
valuable. The reasons for ineligibility included nonresect-
ble disease documented by routine staging (39), missing or
utdated staging procedures (12), no cancer diagnosis (4),
re-PET induction therapy (3), claustrophobia (1), and other
auses (4). The 10 eligible patients excluded for PET pro-
ocol violations included 3 who had induction after PET
efore it was allowed in protocol revisions, 3 who had
ET/CT, 2 who died or withdrew before the PET was done,
nd 2 with specific PET scanning protocol violations.
The mean age (SD) of the 189 evaluable patients was
2.6  11.0 years (range: 36.2-88.5 years); 160 (84.7%)
ere men and 29 (15.3%) were women; 180 (95.2%) were
hite. The Eastern Cooperative Oncology Group/Zubrod
erformance status was as follows: 0, 116 (61.4%); 1, 71
37.6%); and 2, 2 (1.1%). Thirty-seven (19.6%) patients
ere enrolled before the amendment allowing induction
herapy and 152 (80.4%) were enrolled after the amend-
ent. Seventy-three (38.6%) of the patients underwent
ome form of induction chemotherapy and/or radiation ther-
py. All 73 patients who underwent induction therapy were
nrolled after the amendment. Of these, 67 (35.5% of the
otal) of the patients underwent preoperative chemotherapy
nd radiation therapy, 4 (2.1% of the total) underwent
reoperative chemotherapy only, and 2 (1.1%) underwent
reoperative radiation therapy only.
CT revealed that 97 patients (51.3%) were T0, T1, or T2
nd 92 (48.7%) were T3; 166 (87.8%) were N0 and 23
12.2%) were N1; and 187 (98.9%) were M0 and 2 (1.1%)
ere M1a. PET alone showed no abnormal FDG uptake
orresponding to the primary tumor in 17 (9.0%) patients
nd identified the primary tumor in 172 (91.0%). By PET,
and Cardiovascular Surgery ● Volume 133, Number 3 741
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G
TS31 (69.3%) were N0 and 58 (30.7%) were N1; 154 (81.5%)
ere M0, 2 (1.17%) were M1a, and 33 (17.5%) were M1b.
inal histologic type was squamous in 24 (12.7%), adeno-
arcinoma in 159 (84.1%), carcinoma in 2 (1.1%), and other
n 4 (2.1%). Nodal and metastasis agreement between CT
nd PET are displayed in Tables 1 and 2, respectively.
Table 3 displays the CT by PET findings with the status
f the patient regarding confirmatory procedures. There
ere 9 patients (4.8%; 95% CI 2.2%-8.9%) classified as
1b by PET and confirmed as true positive findings. Ad-
itionally, there were 18 patients upstaged by PET from M0
o M1b in whom confirmatory procedures were not done. Of
hese 18 patients, 1 patient had rib and pelvis lesions that
ere still suggestive of M1b disease after confirmatory bone
cintigraphy, 1 patient had a liver/right adrenal lesion that
as still suggestive after ultrasonography, and the other
atients had hilar, cervical, supraclavicular, or other lymph-
denopathy that met the criteria for M1b disease. Thirteen
f these patients had a surgical resection and 5 did not.
hree of the 13 patients undergoing resection despite un-
onfirmed PET suggestion of M1 disease demonstrated
ecurrence in the first 6 months. There were 5 patients
2.6%; 95% CI 0.9%-6.1%) who apparently were upstaged
rom M0 to M1b by PET but who had normal or inconclu-
ive confirmatory procedures. Four of these 5 underwent
esection and none of them had recurrence or progression in
he first 6 months. There was 1 confirmed patient who was
pstaged from M0 to M1a by PET. One additional patient
pparently was upstaged from M0 to M1a with normal or
nconclusive confirmatory procedures suggesting a false
ositive PET.
Adverse events of grade 3 and above are displayed in
able E-2. One of the costs of routine PET and confirmation
f positive findings would be any morbidity incurred by the
onfirmatory procedures. Seven patients (5 M0-M1b; 2 M0-
1a) had negative confirmatory procedures. One patient
nderwent an adrenalectomy for a false positive PET sug-
ABLE 1. Nodal agreement between CT and PET (n  189)
PET: N0 PET: N1
CT: N0 121 (64.0) 45 (23.8)
CT: N1 10 (5.3) 13 (6.9)
alues are n (%).
ABLE 2. Metastasis agreement between CT and PET
n  189)
PET: M0 PET: M1a PET: M1b
T: M0 153 (81.0) 2 (1.1) 32 (16.9)
T: M1a 1 (0.5) 0 (0) 1 (0.5)aalues are n (%).
42 The Journal of Thoracic and Cardiovascular Surgery ● Marcesting an adrenal metastasis. This patient experienced the
orbidity of the adrenalectomy surgery as well as the need
or subsequent therapy for adrenal insufficiency. Another
atient incurred a grade 3 adverse event for a wound com-
lication after a confirmatory procedure for a false positive
ET.
A total of 145 (77.5%) patients went on to have surgery,
2 (22.5%) did not, and in 2 patients the surgical status
annot be determined. Analysis of resection status, stratified
n the use or nonuse of induction therapy, showed a resec-
ion rate of 68% in the patients given induction therapy and
resection rate of 83% in those not given induction therapy
P  .014). The reasons for no resection in evaluable
atients included the following: M1 disease found by PET
nd confirmed (9), M1 disease found by PET and not
onfirmed (2), M1 disease in the liver, peritoneum, or lung
iscovered at exploration but not found by PET (7), decline
r death before surgery (10), patient refusal of surgery (7),
nresectable local tumor at exploration (5), and extensive
1 disease precluding operation (2). Three of the patients
ho underwent resection died perioperatively and 8 (5.6%)
f the remaining 142 patients undergoing resection had a
elapse of their cancer within 6 months of registration to the
rial.
There were 39 patients who were classified as ineligible
or analysis for the primary objective of the trial because the
ndings of the conventional staging evaluation suggested
etastasis. The findings in these patients included lung
odules (22), liver nodules (13), adrenal masses (4), M1
ymph nodes (3), bone lesions (2), ascites, pleural effusion,
nd a suggestive inguinal mass. Some patients had more
han one abnormality on CT, so the total exceeds 39. Of
hese patients, 20 subsequently underwent resection, 15 did
ot undergo resection, and the resection status of the re-
aining 4 is unknown. The 15 patients who did not undergo
esection include 12 who had evidence of metastasis that
ad been identified by the CT scan and confirmed by PET
nd other subsequent tests. The other 3 patients include 1
ho refused surgery for unstated reasons, 1 who declined
urgery after a complete clinical response to induction ther-
TABLE 3. CT by PET findings with confirmation procedure
status (n  189)
CT PET Confirmatory procedures: n (%)
M0/M1a M0 Not required 154 (81.5)
M0 M1a Confirmed positive 1 (0.5)
M0 M1a Falsely positive PET 1 (0.5)
M0 M1b Not done 18 (9.5)
M0 M1b Confirmed positive 9 (4.8)
M0 M1b Falsely positive PET 5 (2.6)
M1a M1b Falsely positive PET 1 (0.5)py, and 1 who was offered photodynamic therapy as an
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G
TSlternative to surgery. In the 20 patients who underwent
esection despite evidence of metastasis on CT scan, many
ad PET results that contradicted the CT and thus the PET
rovided encouragement to consider surgical resection in
he face of CT findings suggestive of metastatic disease.
our (20%) of these 20 had a recurrence within the first 6
onths of resection, in contrast to the 5.6% recurrence rate
t 6 months seen in those patients eligible for the trial.
iscussion
he primary objective of this trial was to evaluate the
sefulness of adding PET to the staging of patients with
esectable esophageal cancer after completion of routine
taging procedures. This trial therefore differs from most
ther series in which incomplete conventional staging was
erformed. The study design determined at the outset that a
% or lower rate of distant metastasis detection would be
onsidered inconsequential (the null hypothesis) and a
reater than 10% rate of metastasis detection would be
onsidered clinically important (the alternative hypothesis).
he actual rate of detection of metastasis, confirmed by
iopsy, was 4.8%. However, in an additional 9.5% of pa-
ients with apparent PET-detected metastases, the PET find-
ngs were accepted by the treating surgeon as evidence
ithout the required confirmation. Accordingly, the overall
ate of detected metastases may be as high as 4.8%  9.5%
r 14.3% (95% CI: 9.6%-20.1%). It is unlikely that the
ctual fraction of true positive PET findings is at the high
nd of the range, since many of the unconfirmed findings
ere noted in patients who subsequently underwent surgical
esection and had no evidence of recurrence or progression
t 6 months.
Limitations of this trial are important to consider. Tech-
ology has advanced since this trial was opened in 1999,
nd the current widespread use of integrated PET/CT could
lter the yield of PET beyond that seen in this study. The
arge number of ineligible patients enrolled in this study led
o a number of exclusions that were not anticipated by the
tudy design. It is possible that the exclusion of such pa-
ients made the enrollment criteria more rigorous than those
dhered to in actual clinical practice, thereby decreasing the
requency of true positive metastatic lesions detected by
ET. Assessment of this dual purpose of PET, for detecting
nsuspected metastasis and also for confirming or excluding
etastasis suspected on the basis of CT findings, was not
art of the intended scope of this trial.
Although it seems obvious that allowing induction ther-
py in a trial such as this would alter the interpretation of the
esults, it is not obvious how such a change would alter the
easured value of PET in this setting. If a falsely PET
egative, but actually positive M1a celiac node was con-
erted to pathologically negative, then induction therapy
ould mask a weakness of PET by making it appear correct b
The Journal of Thoracichen it is not. If a truly positive M1a node was positive on
ET but was converted to negative by induction therapy, it
ould be scored as a false positive and it would make PET
ook worse. Thus, the direction and the severity of the bias
re unknown, but the presence of bias is suspected.
Additionally, the impact of endoscopic ultrasonography
as not anticipated at the outset of this trial and is therefore
ifficult to incorporate into the analysis and interpretation of
hese results. The use of endoscopic ultrasonography was
poradic in the early patients enrolled, but became more
ommonplace toward the end of accrual. Positive findings
esulting from endoscopic ultrasonography, such as the T3,
1, or M1a stage descriptors, would often lead to an ap-
arent change in treatment (ie, induction therapy) even in
he presence of a Tx N0 M0 PET report.
The main assumptions when this trial was developed
ere that M1b disease would absolutely contraindicate sur-
ery and that M1a disease would be a strong relative con-
raindication to surgery. Therefore, the anticipated impact of
he PET findings on the surgical treatment of the enrolled
atients was believed to depend on the rate of detection of
1a and M1b findings. In the analysis, it became apparent
hat several patients did not undergo resection after PET
emonstrated multistation N1 disease. It is therefore possi-
le that the impact of PET on surgical decision making goes
eyond the detection of M1 disease. In addition, when the
tudy was amended to allow induction therapy between PET
nd surgery, the analysis was further complicated by the fact
hat the PET finding of N1 nodal disease could directly or
ndirectly lead to the selection of an induction therapy
trategy. Because a substantial number of patients treated
ith induction therapy never undergo subsequent surgical
esection, it is possible that the impact of PET on surgical
esection rates has been underestimated in this study.
A potential downside to routine use of PET for staging in
hese patients is the burden imposed by the false positive
ET findings. Assuming that all positive findings would be
onfirmed, a false positive PET result might lead to more
nvasive procedures and therefore might result in cost and
orbidity beyond that attributable to the PET procedure
tself. An example in this trial is an individual patient with
pparent M1 disease on PET who underwent an adrenalec-
omy. The adrenal was resected and shown to be normal, the
ET was thus falsely positive, and the patient required
herapy for adrenal insufficiency. Because the positive PET
ndings in this study were not all properly assessed by
onfirmatory studies in accordance with the trial protocol,
he risks and costs that characterize the burden of false
ositive results are likely underestimated here.
One interpretation of our results is that PET for esoph-
geal cancer has many attributes, only one of which is the
etection of M1 disease in patients otherwise believed to
e surgical candidates after routine CT staging. PET can be
and Cardiovascular Surgery ● Volume 133, Number 3 743
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G
TSsed as a confirmatory test when there are indeterminate
bnormalities on CT. There is a growing body of literature
uggesting that the standardized uptake value for FDG in
he primary tumor, a semiquantitative measure of the tu-
or’s glucose metabolism, may help identify patients at
levated risk for recurrence and may, therefore, identify
ppropriate patients for induction therapy or adjuvant ther-
py.6 Another body of literature addresses the hypothesis
hat PET, obtained during or after induction therapy, can
redict pathologic response and identify subsets of patients
ith better and worse prognoses.7-12 None of these specific
ndications was tested by the current trial.
In summary, FDG-PET in patients with esophageal cancer
ithout evidence of metastasis after conventional workup
dentified unsuspected distant metastatic disease in at least
.8% (95% CI: 2.2%-8.9%) of cases. An additional 3.7% (95%
I 1.5%-7.5%) had unconfirmed evidence of M1b disease and
ere treated nonsurgically, at least in part owing to the PET
ndings. In most cases, these PET-detected metastases should
e confirmed before excluding a patient from surgical consid-
ration, since apparent M1 findings by PET in at least 3.7%
95% CI: 1.5%-7.5%) were false positives. An additional 5%
f patients can be expected to harbor metastatic disease that
scapes detection by both CT and PET.
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iscussion
r Mark J. Krasna (Baltimore, Md). First, I wish to congratulate
r Meyers on an excellent presentation. Following up on the
ioneering work at Washington University on PET scanning for
horacic malignancies, the ACSOG undertook two clinical trials to
etermine the role of PET scanning in our specialty. After pre-
enting their findings from Z40 on PET scanning for lung cancer,
he ACOSOG surgeons are now presenting the results of the first
ulti-institutional prospective phase 2 trial for PET scanning in
sophageal cancer to put this new modality in perspective. All the
urgeons who undertook this goal are to be congratulated for their
ompletion of this trial. This in itself is a great accomplishment
nd is an example to us all to study questions in thoracic surgery
horoughly by clinical trial wherever possible.
The objective of this study was to see whether PET scan
voided unnecessary surgery in 5% or more of patients with
sophageal cancer. The primary result of the study may be sum-
arized as follows: PET scan identified suggestive M1 disease,
ncluding M1a and M1b, in 11 patients, or 4.8%. PET scan missed
1 disease in 7 patients who underwent exploration. Also, PET
can found that 31% of the patients had N1 disease, including
xtensive N1, which sometimes led to surgeons avoiding surgery.
his is a little lower than expected for most surgical series, in
hich almost two thirds of patients are found to have N1 disease.
Interestingly, this study also provides a snapshot of the current
ractice among CT surgeons in managing esophageal cancer. Over
8% of the patients were referred for induction chemoradiation
herapy in this study. This adds to the recent “Patterns of Care
urvey” data from the Radiation Therapy Oncology Group that
how the inroads that surgeons have made in incorporating che-
oradiation and surgery in the treatment algorithm for esophageal
ancer, and it is supported by recent phase 2 and phase 3 studies.
nfortunately, this also limits the interpretation of the results, as it
ould have been best to compare PET to pathologic findings in
atients who were undergoing more surgery alone. I have three
uestions.
First, how have you defined the role of surgery in patients with
1a disease? On what basis do you decide not to perform resec-
ion in these patients and those with extensive N1 disease? Second,
hat is the average cost of PET scanning? Do these results really
ustify using this huge outlay in expenditure, in your opinion?
inally, although there were 262 patients who were enrolled, the
neligibility and unevaluable rate was quite high, much higher than
ou expected. Given the borderline significance of these findings,
o the authors think that the results would be different, and how
ould you suggest to us the take-home message be interpreted? In
ther words, what is the current role of PET scan in our practice in
sophageal cancer?
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Meyers et al General Thoracic SurgeryDr Meyers. Thanks for your questions, Dr Krasna. Your first
uestion asked about the role of surgery in M1a, and this trial
ctually left it to the surgeons to make a decision about how to deal
ith their patients once they have had the PET and CT staging. If
were to answer your question, it would represent my personal
trategy for M1a, and it includes very limited surgery. I would
ffer M1a patients surgery only if they had no evidence of distant
etastatic disease and if they underwent induction therapy and
ere good surgical candidates afterward. However, that question
as not addressed by this study in any way at all.
The average cost of a PET scan is around $2000. We did not
ave a corollary cost-effectiveness analysis planned when this
tudy was initiated, but I am sure that we could use these data
o come up with an analysis to look at the benefit and cost
ssociations with PET scanning. I am sure that that would be a
atural follow-on to this study. PET scans cost $2000 apiece,The Journal of Thoracicurgery in only 5% to 8% of the patients, cost is certainly a
onsideration.
Finally, you asked about the question of ineligible patients and
he fallout from the number of patients enrolled to the number of
atients who were actually analyzed and how those results might
iffer. Certainly the screened cohort, before and after exclusions,
s going to differ in that there will be a decrease in the apparent
ield of “new” M1 disease by the PET scan. However, I think that
he exclusions offer as close as to a real estimate of the value of
ET scan that we could report. I think in the single-center studies,
ncluding our own, the enrollment was not as carefully scrutinized
s it was in these patients, and we found that there were quite a
umber of patients with borderline CT abnormalities in whom the
ET scan was used to confirm an abnormal CT finding rather than
o look for something that was undetected by the CT scan. Those
re two different goals. The point of this study was to look at newG
TSnd when you see that it only changed the stage-directed use of detection of otherwise unsuspected metastatic disease.
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TSABLE E1. Enrolling institutions
kron General Hospital
llegheny Cancer Center
aylor University Medical Center
uke University Medical Center
ood Samaritan Hospital
ameson Hospital
atter Day Saints Hospital
assachusetts General Hospital
edical College of Virginia
edical University of South Carolina
emorial Sloan-Kettering Cancer Center
hio State University, Arthur G. James Cancer Hospital
rovidence Portland Medical Center
tanford University
tate University of New York, Upstate Medical University
wedish Medical Center
niversity of Alabama at Birmingham
niversity of Colorado
niversity of Maryland
niversity of Tennessee
ashington University Medical Center
estmoreland Hospital
illiam Beaumont Hospital
TABLE E2. Adverse events grade 3 and above
Adverse events Grade 3 Grade 4 Grade 5 (death)
Nausea 1 (0.5)
Effusion, pleural 2 (1.1)
Dehydration 1 (0.5)
Pancreatitis 1 (0.5)
Pneumonitis 1 (0.5) 1 (0.5)
Adult respiratory distress
syndrome
1 (0.5) 1 (0.5)
Arrhythmia 1 (0.5)
Ischemia/infarction 1 (0.5)
Pain, abdominal 1 (0.5)
Infection, no antigen
neutralizing capacity
1 (0.5)
Thrombocytopenia 1 (0.5)
Fistula, esophagus 1 (0.5) 1 (0.5)
Hyperglycemia 2 (1.1)
Pneumothorax 1 (0.5)
Wound, noninfectious 1 (0.5)
Hemorrhage 1 (0.5)
Febrile neutropenia 1 (0.5)
Infection 2 (1.1)
Neurologic 1 (0.5)
Pain 1 (0.5)
Pulmonary 2 (1.1) 1 (0.5)
Diaphragm rupture 1 (0.5)
Dysphagia 1 (0.5)
Leukopenia 1 (0.5)
Thrombosis 1 (0.5)
Arrhythmia, supraventricular
tachycardia
1 (0.5)
Acidosis 1 (0.5)
Apnea 1 (0.5)
Endocrine 2 (1.1)
Infection, no antigen
neutralizing capacity
1 (0.5) 2 (1.1)
Hematemesis 1 (0.5)
Values are n (%).45.e1 The Journal of Thoracic and Cardiovascular Surgery ● March 2007
